TECH PROFILE

Fundación Instituto de Investigación Sanitaria de Santiago de Compostela

Sepcom

Business area
Discovery

Market sector
Inflammatory diseases, , rheumatic diseases

Medical Indication
Sepsis

Research goal

a) Development of a novel pharmaceutical composition comprising corticoids and a repurposed drug to use it in the prevention/treatment of sepsis and/or toll like receptor 4 (TLR4) -mediated inflammatory processes.
b) Development of a novel pharmaceutical composition comprising corticoids and a repurposed drug that allows the reduction of the corticoid dose to treat inflammatory processes without reducing its anti-inflammatory effect. Additionally, the pharmaceutical composition also reduces the catabolic effect of corticoids in the bone without affecting its anti-inflammatory activity.

Problem to solve

a) The mortality of the patients diagnosed with sepsis is very elevated, more that 50%. The majority of these deaths are associated to an excessive systemic innate immune response. Currently there is no an effective treatment to reduce this excessive activation. As a result, any development that can be added to the current therapy with corticoids will be very well received in the market.
b) Currently the use of corticoids is a gold standard for the treatment of many rheumatic diseases. However, the potent anti-inflammatory effect of corticoids is linked in a dose response manner to severe side effects. As a result, any development that can reduce the use of corticoids and compensate their catabolic activities in key musculoskeletal tissues will be easily introduced in the market due to a lack of competence.

Innovation

The key finding of this invention is the identification of combined effect of an already used drug with corticoids. This combination allows the preservation of their anti-inflammatory effect reducing their working concentration as well as their intrinsic catabolic activity.

Market opportunity

The sepsis and septic shock space across the seven major pharmaceutical markets (7MM) of the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan is set to grow from $2.8 billion in 2016 to $5.9 billion by 2026, representing a compound annual growth rate (CAGR) of 7.9%, according to GlobalData.

Research team

Musculoskeletal Pathology Research Group of the Health Research Institute of Santiago de Compostela.

- **Rodolfo Gómez Bahamonde**: Principal Investigator

Intellectual property

Patent Request.

Development stage:



Available for: *Licensing, co-development*

innotransfer.fidis.santiago@sergas.es
+34 981 951 195
www.fundacionidisantiago.es